Girard Gibbs LLP is investigating what they claim may be securities fraud by Schering-Plough Corp., Inc. and certain of its executives between July 24, 2006 and January 14, 2008.
The firm apparently suspects that Schering-Plough issued a series of material misrepresentations in its filings with the Securities and Exchange Commission and press releases which artificially inflated the value of Schering-Plough shares. They also suspect that Schering-Plough misled investors regarding the increased efficacy of Vytorin, a combination of Zetia and Zocor, over the cheaper generic form of Zocor (simvastatin), alone, and delayed disclosing results of the ENHANCE study demonstrating that Vytorin was not more effective than Zocor.
On January 14, 2008, investors learned there were severe safety and efficacy issues related to the Schering-Plough’s sale of Vyotorin and Girard Gibbs claims that Schering-Plough may have purposefully delayed the publication of a study showing that Vytorin was neither safe nor effective.
Dr. Rost is a pharma litigation consultant and pharmaceutical marketing expert. He is also the author of Killer Drug and The Whistleblower.
What were the safety issues?
Posted by: anonymous | February 22, 2008 at 12:09 PM